KYMERA THERAPEUTICS I

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

25 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

21 Aug 2024 11:15:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

19 Aug 2024 22:45:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Proposed Public Offering

19 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

31 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

09 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

08 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

14 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

01 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

23 May 2024 17:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

22 May 2024 11:20:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

14 May 2024 10:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

08 May 2024 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

02 May 2024 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

08 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

08 Mar 2024 10:00:00 By Nasdaq GlobeNewswire